In 2022, an outbreak of mpox (formerly known as monkeypox) garnered global attention, leading to a public health emergency declaration by the WHO.
In 2023, a new variant of the virus emerged, resulting in over 21,000 reported cases by August 2024. WHO declared the epidemic a public health emergency of international concern in August 2024.
The Project BioShield Act of 2004 aimed to defend against bioterrorism by accelerating the research and availability of medical countermeasures. This led to the development of Jynneos, the first approved monkeypox vaccine developed by Bavarian Nordic.
A second smallpox vaccine, ACAM2000, was approved for use against mpox by the US Food and Drug Administration last month. This second vaccine is manufactured by the controversial Emergent BioSolutions.
Among ACAM2000 horrifying adverse effects is that the live vaccinia virus, which the vaccine contains, can be transmitted to persons who have close contact with the vaccinee causing the same horrific adverse effects, including death.
How could ACAM2000 have gotten approval in the first place? Former US Assistant Secretary of Health and Human Services (Preparedness and Response) Robert Kadlec and his connections might provide the answer.
Hellbound and Down 